Batavia Biosciences, Inc.
Batavia Biosciences is a leading contract development and manufacturing organization (CDMO) dedicated to supporting companies in viral vector and vaccine development, providing tailored process development to bring concepts to life. Their expertise ensures a streamlined path from initial idea to compliant, scalable production, with a focus on reducing costs and increasing success rates in biopharmaceuticals. They operate state-of-the-art facilities in Europe and the US, and are part of the CJ CheilJedang global family, building a strong presence in global health. The company specializes in process development, GMP late-stage and commercial manufacturing for viral vectors, vaccines, and oncolytic viruses, supporting the entire journey from R&D to full market launch. They have expanded their facilities and capabilities, including the development of innovative platforms like HIP-Vax and SCOUT, and are actively involved in global health initiatives such as vaccine development for Rift Valley fever, Marburg virus, and other infectious diseases. Their collaborations include partnerships with VBC, MEVAC, and IAVI, focusing on vaccine manufacturing in Egypt, and integrating advanced technologies like continuous chromatography to enhance production efficiency and capacity.
Industries
Nr. of Employees
medium (51-250)
Batavia Biosciences, Inc.
Leiden, Zuid-Holland, The Netherlands, Europe
Products
Microfacility concept for localized inactivated vaccine production
A contained microfacility concept that integrates fixed-bed cultivation and downstream purification to enable localized, small-footprint production of inactivated vaccines with simplified containment requirements.
Validated chromatographic method for strain-resolved viral quantification
A chromatographic method using combined gradient strategies to resolve and quantify multiple viral strains in a single run for process development and release testing.
Modular GMP multi-suite manufacturing facility (project)
Design concept and implementation plan for a modular, multi-suite GMP facility capable of supporting adherent fixed-bed and suspension platforms, on-site fill/finish and large-scale production for clinical and commercial supply.
Microfacility concept for localized inactivated vaccine production
A contained microfacility concept that integrates fixed-bed cultivation and downstream purification to enable localized, small-footprint production of inactivated vaccines with simplified containment requirements.
Validated chromatographic method for strain-resolved viral quantification
A chromatographic method using combined gradient strategies to resolve and quantify multiple viral strains in a single run for process development and release testing.
Modular GMP multi-suite manufacturing facility (project)
Design concept and implementation plan for a modular, multi-suite GMP facility capable of supporting adherent fixed-bed and suspension platforms, on-site fill/finish and large-scale production for clinical and commercial supply.
Services
End-to-end viral vector process development and scale-up
Custom upstream and downstream development from lab optimisation through tech transfer and scale-up to clinical and commercial production, including analytical method transfer and QC integration.
GMP clinical and commercial manufacturing
End-to-end GMP manufacturing services including upstream production (adherent and suspension), downstream purification, fill/finish, labeling, storage and shipment for clinical and commercial supply.
Analytical assay development and validation with integrated QC
Development, transfer and validation of fit-for-purpose analytical methods for R&D, in-process control and product release executed in collaboration with QC units to enable GMP release.
Integration of continuous chromatography into downstream workflows
Development and piloting of continuous column-free chromatography platforms and integration into downstream purification trains to improve throughput, recovery and cost-of-goods for viral vector production.
Technology transfer, licensing and local manufacturing enablement
Provision of tech transfer packages, licensing of processes and analytical methods, and on-the-ground support to enable regional partners to establish compliant vaccine manufacturing capabilities.
Clinical material manufacture for early-phase trials
Production of clinical-grade material for Phase I/IIa studies, including process development, GMP manufacture and release testing to support clinical programs and consortium studies.
End-to-end viral vector process development and scale-up
Custom upstream and downstream development from lab optimisation through tech transfer and scale-up to clinical and commercial production, including analytical method transfer and QC integration.
GMP clinical and commercial manufacturing
End-to-end GMP manufacturing services including upstream production (adherent and suspension), downstream purification, fill/finish, labeling, storage and shipment for clinical and commercial supply.
Analytical assay development and validation with integrated QC
Development, transfer and validation of fit-for-purpose analytical methods for R&D, in-process control and product release executed in collaboration with QC units to enable GMP release.
Integration of continuous chromatography into downstream workflows
Development and piloting of continuous column-free chromatography platforms and integration into downstream purification trains to improve throughput, recovery and cost-of-goods for viral vector production.
Technology transfer, licensing and local manufacturing enablement
Provision of tech transfer packages, licensing of processes and analytical methods, and on-the-ground support to enable regional partners to establish compliant vaccine manufacturing capabilities.
Clinical material manufacture for early-phase trials
Production of clinical-grade material for Phase I/IIa studies, including process development, GMP manufacture and release testing to support clinical programs and consortium studies.
Expertise Areas
- Viral vector process development
- Viral vaccine development and manufacturing
- Bioprocess intensification and fixed-bed cultivation
- Downstream purification including continuous chromatography
Key Technologies
- Fixed-bed (adherent) bioreactors
- High-cell-density cultivation
- Tangential flow filtration (TFF)
- Continuous column-free chromatography (real moving bed)